In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.

  On December 12, Janssen announced the 48-week results of the head-to-head PKECLIPSE Phase III study of Tremfya (guselkumab) and Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis. In the Tremfya treatment group, the psoriasis area and severity index improved by more than 90% (PASI 90, primary… Continue Reading Johnson & Johnson’s new psoriasis PK wins, Novartis Cosentyx is counterattacked

  Genentech announced on December 6 that the FDA approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) for first-line treatment of metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations. . The approval is based on data from a multicenter, open-label, randomized, controlled… Continue Reading Roche PD-L1 first-line therapy for lung cancer

  Biopharma Dive, a biopharmaceutical website, recently selected the annual pharmaceutical company (Mersha East), the annual biotechnology company (Spark Therapeutics), the annual CEO (Emma Walmsley, GSK), the annual transaction (Takeda $62 billion acquisition of Shire), the annual innovation (RNA Targeted therapy), an annual new drug (Ajin/Nuohua migraine drug Aimovig).  … Continue Reading BioPharma: Six “most” in 2018

  On November 30, Pfizer announced a settlement with AbbVie on a worldwide patent litigation against adalimumab biosimilars. Under the agreement, in the European market, Pfizer’s adalimumab biosimilars will be available for sale upon approval by the EMA. However, in the US market, Pfizer needs to market adalimumab biosimilars on… Continue Reading Pfizer and AbbVie reach a settlement, delaying the launch of Humira-like drugs in the US

  On November 26, He Jiankui, a scientist at Southern University of Science and Technology, announced that a pair of genetically edited babies named Lulu and Nana were born in China in November. The genes of the twins have been modified to make them naturally resistant to AIDS after birth.… Continue Reading Chinese scientists claim that the world’s first genetic editing baby is born! Naturally resistant to AIDS

  On November 23, the application for the Bayer prostate cancer new drug Xofigo (Rainium Chloride [223Ra] Injection) was officially accepted by CDE. Xofigo was first approved by the FDA on May 15, 2013 for the treatment of advanced bone metastases in castration-resistant prostate cancer. In the Phase 3 ALSYMPCA… Continue Reading Bayer prostate cancer new drug Xofigo applied for listing in China

  Recently, Sage Therapeutics issued a statement saying that the FDA has extended the PDUFA date for priority review of new drug applications for its new drug Zulress (brexanolone) for the treatment of postpartum depression. This means that the previously disclosed PDUFA on December 19, 2018 will be extended by… Continue Reading FDA delays approval of new postpartum depression drug brexanolone, requiring risk assessment and mitigation strategies

  On November 21, Taiwan’s OBI Pharma announced that the FDA has granted OBI-888 the right to treat orphan drugs for pancreatic cancer. OBI-888 is a first-in-class passive immunotherapy treatment of monoclonal antibody against Globo H, a tumor cell surface antigen, whose mechanism of action is antibody-dependent cytotoxicity, antibody-dependent macrophage… Continue Reading Taiwan’s Hao Ding Harvest FDA’s third orphan drug qualification: OBI-888 for the treatment of pancreatic cancer

  Last year, the rumor that Pascal Soriot had to change to the CEO of Teva was very rampant, and the reasons for his departure were constant. Pascal Soriot himself declined to comment directly on the matter and later sent an internal memo to the staff, urging them to continue… Continue Reading Rumors: AstraZeneca will replace the CEO? Successor candidates may be generated internally